MAM
LENZ

Marquette Asset Management’s LENZ Therapeutics LENZ Stock Holding History

Marquette Asset Management’s Portfolio LENZ Stock Details LENZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-5,865
Closed -$131K – 209
2024
Q1 		$131K Sell
5,865
-1
-0% -$21 0.02% 95
2023
Q4 		$108K Hold
5,866
– – 0.02% 102
2023
Q3 		$102K Hold
5,866
– – 0.02% 101
2023
Q2 		$107K Hold
5,866
– – 0.03% 114
2023
Q1 		$101K Buy
+5,866
New +$94.9K 0.03% 109

Other funds holding LENZ

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
AWG
Alpha Wave Global New York $791M AUM 113.77% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
7IH
72 Investment Holdings Stamford, Connecticut $49.6M AUM 684.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Marquette Asset Management's LENZ Position: Q2 2024 in Review

Marquette Asset Management sold out of LENZ Therapeutics (LENZ) in Q2 2024, closing a stake of 5,865 shares — an estimated $131K sold.

Marquette Asset Management first reported a position in LENZ in Q1 2023 and held it in 5 quarters. The position peaked at $131K in Q1 2024. 65 funds tracked by Wall St. Rank hold LENZ as of Q2 2024.

  • Marquette Asset Management reported no remaining LENZ Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Marquette Asset Management sold 5,865 LENZ Therapeutics shares in Q2 2024, an estimated $131K.
  • Marquette Asset Management first reported a position in LENZ Therapeutics in Q1 2023 and held it in 5 quarters.
  • Marquette Asset Management's LENZ Therapeutics position peaked at $131K in Q1 2024.
  • 65 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q2 2024.

Based on Marquette Asset Management's 13F filing for Q2 2024, filed 14 Aug 2024.